Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
31 Jul, 2025 (Thursday)

            
ALI HEALTH(241)
Analysis:
Ali Health operates primarily in two major areas: pharmaceutical e-commerce and healthcare and digital services. The pharmaceutical e-commerce business includes the Tmall Health platform and self-operated pharmaceutical businesses, while the healthcare and digital services business encompasses healthcare services and digital tracking services. The Tmall Health platform, a leading online pharmaceutical and healthcare product service platform in China, has seen continuous growth in annual GMV (Gross Merchandise Volume) and active users. As of March 31, 2025, the number of active merchants on the platform surged 35% year-on-year to 48,300, with online SKUs increasing over 91% to 133 million. The integration of advertising services has further enhanced the business model’s completeness for the Tmall Health platform, enabling the group to provide more customized services to merchants while actively promoting their business growth, improving merchant experience and satisfaction, and achieving rapid year-on-year revenue growth. The self-operated business focuses on providing comprehensive and inclusive pharmaceutical and healthcare services, including prescription drugs, over-the-counter (OTC) drugs, health supplements, medical devices, and contact lenses, to consumers from platforms such as Tmall, Taobao, Alipay, and Ele.me. For the year ended March 31, 2025, the self-operated pharmaceutical business recorded revenue of RMB 26.124 billion, up 10% year-on-year. The number of annual active consumers and ARPU (Average Revenue Per User) for the online self-operated store continued to grow, with SKUs increasing 33.6% year-on-year to 1.23 million.
In the healthcare and digital services business, the group continues to enhance the professional healthcare service experience, offering an integrated online and offline healthcare system through channels such as Tmall, Taobao, Alipay, AMap, DingTalk, Freshippo and Quark. Services include traditional Chinese medicine, physical examinations, consultations, appointment registrations, vaccinations, dental care, mental health, vision care, and nursing. As of March 31, 2025, the number of licensed physicians, pharmacists, and nutritionists contracted to provide online health consultation services grew to nearly 240,000. The group’s internet hospital business continues to operate digital solutions for various disciplines, successfully expanding from oncology and autoimmune specialties to neurosurgery, orthopedics, psychiatry, and gynecology. Xiaolu TCM (Traditional Chinese Medicine) saw its registered TCM practitioners grow to 140,000, with 137 dispensing centers established. Additionally, an AI-assisted TCM diagnostic system was launched, fully integrated with the DEEPSEEK reasoning model on the Alibaba Cloud Bailian platform, leveraging millions of clinical case data for improved efficiency in scenarios such as physician-assisted consultations.
On March 19, 2025, the National Healthcare Security Administration, Ministry of Human Resources and Social Security, National Health Commission, and National Medical Products Administration jointly issued the Notice on Strengthening the Collection and Application of Drug Trucking Codes in Healthcare and Work-Related Injury Insurance. This initiative promotes full-process drug tracking through drug tracking codes, covering production, distribution, and usage stages, and encourages comprehensive collection and application in healthcare and work-related injury insurance, ultimately achieving full coverage of tracking code collection in medical institutions. The group’s “Ma Shang Fang Xin” tracking platform actively responds to national policy support, further advancing full value chain coverage for drug production, distribution, retail pharmacies, and medical institutions, maintaining efficient and healthy development of its platform business.
(I do not hold the above-mentioned stock.)
Strategy:
Buy-in Price: $4.85, Target Price: $5.35, Cut Loss Price: $4.65


BILIBILI-W(9626)
Analysis:
In Q1 2025, the company's net revenue reached RMB 7.00 billion (RMB, the same below) with a year-on-year increase of 24%. Value-added service revenue reached RMB 2.81 billion with a year-on-year increase of 11%, primarily due to increased revenue from live streaming and other value-added services. Advertising revenue reached RMB 2.00 billion with a year-on-year increase of 20%, primarily driven by strong growth in performance-based advertising revenue. Mobile game revenue reached RMB 1.73 billion with a year-on-year increase of 76%, primarily driven by the strong performance of the company's exclusively licensed game " San Guo: Mou Ding Tian Xia," which is expected to become a key growth driver for the company's gaming business. IP-based derivatives and other revenue reached RMB 467 million with a year-on-year decrease of 4%. Gross profit reached RMB 2.54 billion with a year-on-year increase of 58%, with a gross profit margin of 36.3%. Net loss narrowed by 99% year-on-year to RMB 10.7 million. The average daily active users reached 107 million, and the average monthly active users reached 368 million, both new records. The average daily usage time reached 108 minutes, and the average monthly paying users also reached a record high of 32 million, demonstrating high user activity. The average user age in 2025 is 26, users are young generation, who generally possess strong spending power and a certain degree of brand loyalty. Bilibili has consistently focused on developing high-quality long-form video. AI will continue to empower the company's video content and advertising, further improving user experience and platform operational efficiency. We believe that given the current AI-driven industry uptrend, the company's valuation still has room for growth.
Strategy:
Buy-in Price: $179.00, Target Price: $199.70, Cut Loss Price: $170.00



JIANGXI COPPER (358.HK) - The work plan for stabilizing growth in key industries will be released soon, boosting market sentiment

Company Profile

Jiangxi Copper is a leading copper producer in China, primarily engaged in copper mining, smelting, processing, and sales. The company boasts abundant copper resource reserves and advanced production technologies. Its products include copper concentrates, copper cathodes, and copper materials, which are widely used in industries such as power, construction, and transportation.

Performance Highlights

In Q1 2025 (According to Chinese accounting standards), the company's revenue was RMB 111.61 billion, down 8.9% year-on-year; net profit attributable to shareholders after deducting non-recurring items was RMB 2.48 billion, up 37.08% year-on-year, mainly due to the fair value changes in financial assets and liabilities and related disposal gains and losses; EPS was RMB 0.57, up 14% year-on-year; net operating cash flow was RMB 558 million, up 109.2% year-on-year, mainly due to the increase in notes payable and accounts payable. In 2024, the company's revenue was RMB 519.25 billion, down 0.21% year-on-year; net profit attributable to shareholders was RMB 6.9 billion, up 2.3% year-on-year; EPS was RMB 2.00, up 2.56% year-on-year; dividend per share was RMB 0.7 in 2024, and the dividend payout ratio has increased for three consecutive years, indicating that the company attaches importance to shareholder returns.

Chart 1: Dividend payout ratio
"Chart
Resources: Annual Report, PSHK

Copper and gold production grew steadily

In 2024, the company's cathode copper production was 2.29 million tonnes with a year-on-year increase of 9.28%, and sales were 2.29 million tonnes with a year-on-year increase of 9.24%; gold production was 118.26 tonnes with a year-on-year increase of 4.99%, and sales were 119.09 tonnes with a year-on-year increase of 5.65%. The company gave guidance on the production and operation plan for 2025: production of 200,000 tonnes of copper concentrate, 2.37 million tonnes of copper cathode, 139 tonnes of gold, 1,243 tonnes of silver, 6.53 million tonnes of sulphuric acid and 2.01 million tonnes of copper processing materials.

Chart 2: Analysis for production and sales
"Chart
Resources: Annual Report, PSHK

The Aynak copper mine project has been restarted, and the company's production capacity is expected to be further expanded

The Mes Aynak copper mine project in Afghanistan, in which the company participated, is a key part of China's overseas resource layout. However, due to factors such as safety and cultural protection, the project has gone through 16 years of twists and turns and was finally restarted in July 2024. The company holds a 25% stake in the project, with MCC Group as the lead party and both parties jointly operating. The Mes Aynak copper mine is the world's second largest undeveloped copper mine, with proven resources of 662 million tonnes, copper metal resources of approximately 11.08 million tonnes, and an average grade of 1.67%. After reaching full production, it is expected to produce 220,000 tonnes of refined copper annually, which is expected to further expand the company's production capacity and alleviate China's copper resource consumption gap.

Becoming the largest single shareholder of SolGold

In March 2025, Jiangxi Copper (Hong Kong) Investment Co., Ltd., a wholly-owned subsidiary of the Company, signed a share purchase agreement with SolGold Canada Inc. ("SolGold Canada"), whereby Jiangxi Copper Hong Kong Investment purchased 157 million shares (approximately 5.24% of its issued shares) of SolGold Plc (SolGold), a listed company in London and Toronto, held by SolGold Canada, for a total transaction price of US$18.07 million. Prior to this transaction, Jiangxi Copper Hong Kong Investment already held 209 million shares of SolGold. After the completion of this transaction, Jiangxi Copper Hong Kong Investment will hold a total of 366 million shares of SolGold (approximately 12.19% of its issued shares). After this transaction, Jiangxi Copper will become the largest single shareholder of SolGold. SolGold is a mineral exploration and development company headquartered in Perth, Australia. The core asset is 100% equity of the Cascabel project in Ecuador. The Alpala mineral deposit, the main project, currently has the following proven, controlled and inferred resources: 12.2 million tonnes of copper, 30.5 million ounces of gold, and 102.3 million ounces of silver, of which the proven and probable reserves are: 3.2 million tonnes of copper, 9.4 million ounces of gold, and 28 million ounces of silver. The project has completed a pre-feasibility study. Sol Gold also has dozens of exploration projects at different stages in Ecuador and other places. Jiangxi Copper said that this transaction is in line with the company's development strategy, which will help enhance the company's industry status and help the two companies complement each other's strengths, develop synergistically and enhance their value.

Successful deployment in Kazakhstan

The Bakuta Tungsten Mine Project is one of the key projects in the capacity cooperation framework between China and Kazakhstan. The project is jointly funded by Jiangxi Copper Group Co., Ltd., Hengzhao International (Hong Kong) Co., Ltd., and China Railway Construction Corporation Limited. The project company in Kazakhstan is Jetsu Tungsten Industry Co., Ltd. The Bakuta Tungsten Mine has a tungsten ore reserve of about 120 million tonnes. It is designed to adopt open-pit mining with an annual mining scale of 3.3 million tonnes. Two years after it is put into production, the mining scale will be increased to 4.95 million tonnes per year through the use of waste disposal technology. The first phase of the Bakuta Tungsten Mine project is expected to achieve commercial production in Q3 2025, and the second phase of the expansion plan is expected to start in Q1 2027, indicating that the company has successfully laid out in Kazakhstan and has taken a further step in its international layout.

Investment Thesis

The International Copper Study Group (ICSG) released its monthly report on June 24th, showing that global copper mine production increased by approximately 2% year-over-year to 7.53 million tonnes in the first four months of 2025, with concentrate production increasing by 2.2%. Global refined copper production increased by approximately 3.2% year-over-year to 9.42 million tonnes, and global apparent refined copper demand increased by approximately 3.3% year-over-year to 9.18 million tonnes, with supply slightly exceeding demand. The ICSG's Global Copper Mine and Refined Copper Market Outlook (2025–2026) report indicates that global refined copper production is projected to grow by 2.9% in 2025 and 1.5% in 2026. Global refined copper consumption is projected to grow by 2.4% in 2025, reaching 28 million tonnes. Global refined copper consumption is projected to reach 28.52 million tonnes in 2026. The global refined copper market is projected to have a surplus of 289,000 tonnes in 2025 and 209,000 tonnes in 2026. We believe that while the refined copper market may experience an oversupply by 2025, demand remains strong. New energy vehicles and home appliance consumption, benefiting from the trade-in policy, will become key growth drivers for global copper consumption. Due to the recent impact of the Sino-US trade war, China has reduced its imports of scrap copper from the United States, which is expected to further increase China's refined copper consumption. The Ministry of Industry and Information Technology recently held a press conference, announcing the implementation of a new round of work plans to stabilize growth in ten key industries, including steel, nonferrous metals, and petrochemicals. This plan aims to promote structural adjustments, optimize supply, and eliminate outdated production capacity in key sectors, boosting market sentiment and potentially supporting copper prices in the short term.

Chart 3: Price of LME Copper
"Chart
Resources: WIND, PSHK

We forecast the company's operating revenue to reach 516.65 billion yuan, 542.48 billion yuan, and 558.76 billion yuan in 2025-2027 respectively. BVPS are 23.8, 25.1, and 26.5 yuan, corresponding to P/B of 0.65x, 0.61x, and 0.58x. We believe the company has medium-term growth potential and assign a target price of HK$18.22 in 2025, corresponding to a P/B of 0.7x. We maintain the “Accumulate" rating. (Current price as of July 29)

Risk Factors

1) Changes in the macroeconomic environment;
2) Market environment changes;
3) Product price fluctuations;
4) Impact of safety incidents;
5) Exchange rate fluctuations;
6) Product substitution risks;
7) Environmental risks.

Financials

"Financials"

Current Price as of: 29 Jul
Source: PSHK Est.

Download PDF version...




Recommendation on 31-7-2025
RecommendationAccumulate
Price on Recommendation Date$ 16.800
Suggested purchase priceN/A
Target Price$ 18.220
Writer Info
Margaret Li
(Research Analyst)
Tel: +852 2277 6535
Email:
margaretli@phillip.com.hk

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2025 Phillip Securities (HK) Ltd. All Rights Reserved.